Traditionally, BMI and simple body weight measurements have served as the cornerstone metrics for estimating health risks related to cardiovascular and metabolic disorders. However, BMI’s inherent limitations—primarily its failure to differentiate between muscle mass and fat or their respective anatomical distributions—have prompted a search for better indicators. This new research confronts that gap head-on by employing deep learning algorithms capable of dissecting complex MRI data to precisely quantify subcutaneous fat, visceral adipose tissue, skeletal muscle volume, intramuscular fat, and muscle quality.

The study cohort, drawing from the extensive UK Biobank and German National Cohort, encompasses 66,608 participants with a mean age approaching 58 years. Their body composition metrics were normalized for age, sex, and height, yielding z-scores that represent individual deviation from population-adjusted norms. This normalization is crucial to accurately gauge risk, as muscle and fat distribution naturally fluctuate throughout the lifespan and differ markedly between sexes and body sizes.

One of the critical revelations from this research highlights that visceral fat—fat stored around internal organs—is associated with a 2.26-fold increased risk of developing diabetes. This finding reaffirms the pathogenic role of visceral adiposity but importantly places it within a framework of nuanced risk assessment informed by personalized body composition profiles rather than crude BMI scores.

Equally transformative is the insight into muscle quality and quantity. High levels of intramuscular fat, indicative of poor muscle quality, correlated with a 1.54-fold increased risk of major cardiovascular events. Meanwhile, a low skeletal muscle mass independently predicted a 1.44-fold higher risk of all-cause mortality, underscoring muscle not just as a mechanical structure but as a vital metabolic organ whose integrity impacts survival beyond traditional cardiometabolic risk factors.

These findings challenge the medical community to rethink how patient risk profiles are constructed and suggest that future clinical protocols might incorporate automated AI-driven imaging tools to routinely assess muscle and fat parameters during standard imaging exams. The AI framework developed for this study is open-source and fully automated, able to extract precise body composition metrics from whole-body MRI scans with minimal human intervention, enhancing reproducibility and clinical scalability.

From a technical perspective, the research team leveraged convolutional neural networks trained on massive annotated datasets to segment and quantify multiple tissue compartments. This approach surpasses older techniques like dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA), which cannot discern intramuscular fat fractions or provide detailed anatomical fat distributions with high accuracy.

The study also generated reference curves that map body composition trajectories throughout the aging process, stratified by sex and height. Such standardized references are invaluable not only for risk stratification but also for monitoring therapeutic interventions, enabling clinicians to differentiate between beneficial fat loss and detrimental muscle wasting, particularly relevant in contexts like weight-loss treatments utilizing GLP-1 receptor agonists.

Importantly, this novel AI-powered analytical framework can apply to a range of existing imaging modalities beyond dedicated whole-body MRI scans. Routine chest or abdominal CTs and MRIs, commonly acquired in clinical practice, harbor untapped data on muscle and fat composition that, with this technology, can be extracted and harnessed for improved patient care without additional imaging burden.

The implications extend beyond metabolic and cardiovascular medicine. The capability to finely characterize body composition holds promise for oncology, where muscle loss (sarcopenia) and fat distribution influence treatment toxicity, survival outcomes, and cancer recurrence. Validating these reference standards in clinical populations forms the next frontier of this research, fine-tuning diagnostic tools tailored for diverse disease contexts.

This research signifies a pivotal shift toward precision medicine driven by data-rich, AI-enabled imaging analytics. It propels the medical field toward a future where personalized body composition metrics will be seamlessly integrated into routine diagnostics, facilitating earlier detection of risk, more informed treatment decisions, and personalized monitoring of disease progression and therapy response.

By turning the hidden layers of everyday imaging data into actionable clinical insights, the study paves the way for a new paradigm in health care—one that recognizes the multifaceted nature of body composition as a critical determinant of overall health and disease risk, beyond the simplistic measures of weight and height.

Subject of Research:
People

Article Title:
Body Composition in the General Population: Whole-body MRI-derived Reference Curves from Over 66,000 Individuals

News Publication Date:
5-May-2026

Web References:
– Radiology Journal: https://pubs.rsna.org/journal/radiology
– Radiological Society of North America: https://www.rsna.org/
– Patient Information on MRI: http://www.radiologyinfo.org

Keywords:
Artificial intelligence, Body size, Imaging, Magnetic resonance imaging, Diabetes, Cardiovascular disorders

Traditionally, cardiometabolic risk prediction algorithms have been developed with the general population in mind, often targeting middle-aged or older adults. This approach has inherently neglected the unique physiological and lifestyle factors prevalent in younger cohorts, especially those grappling with psychosis. PsyMetRiC 2.0 bridges this divide by utilizing a refined algorithm, honed through the rigorous analysis of anonymized health data from over 25,000 young people with psychosis in the United Kingdom, whose clinical trajectories were tracked longitudinally over two decades.

The methodology employed is a landmark in predictive modeling: by harnessing real-world electronic health records, researchers created a model capable of predicting three critical outcomes. Within one year, it estimates significant weight gain; over six years, the onset of metabolic syndrome; and within ten years, the development of type 2 diabetes. These outcomes were chosen not merely for their clinical relevance but also for their resonance with patient priorities, ensuring the tool’s recommendations are grounded in shared decision-making principles.

What differentiates PsyMetRiC’s approach is its conscientious design for utility and fairness. It was rigorously validated across multiple international cohorts, including populations in Spain, Switzerland, Finland, the Netherlands, Canada, Hong Kong, and Australia, demonstrating robust predictive performance beyond the UK. Furthermore, the designers incorporated feedback from clinicians, carers, and those with lived experience of psychosis, in partnership with organizations such as the McPin Foundation and The Centre for Mental Health. This collaborative process ensured that the tool not only delivers precise risk assessments but also communicates these risks in a manner that is accessible, culturally sensitive, and motivating for patients.

At the core of PsyMetRiC 2.0’s architecture is advanced statistical analysis and machine learning techniques applied to large-scale, longitudinal datasets. By identifying complex interactions between demographic factors, clinical presentations, medication regimens—particularly antipsychotic-induced metabolic side effects—and lifestyle parameters like diet, exercise, and smoking, the algorithm provides personalized risk profiles. The predictive models incorporate both fixed and dynamic variables, accounting for changes in health status over time, which enhances their clinical relevance in monitoring disease progression and guiding timely interventions.

A significant achievement of PsyMetRiC is its certification by the UK Medicines & Healthcare products Regulatory Agency (MHRA) as a Class 1 Medical Device. This regulatory endorsement is historic within psychiatry, underscoring the tool’s safety, efficacy, and readiness for integration into routine clinical workflows. Its deployment offers a paradigm shift, encouraging clinicians to move beyond reactive care and towards proactive, prevention-oriented strategies tailored to the complex needs of young people with severe mental illness.

The clinical implications of deploying PsyMetRiC extend beyond individual patient outcomes. People living with psychosis experience substantially reduced life expectancy, averaging a 15-year gap compared to the general population, predominantly due to preventable cardiometabolic diseases. Early identification of risk allows for the initiation of lifestyle modifications and pharmacological treatments—such as metformin or statins—aimed at mitigating weight gain and metabolic disturbances. The availability of a quantifiable risk score also facilitates nuanced conversations between healthcare providers and patients, helping dismantle barriers related to health literacy and stigma.

Emphasizing patient engagement, PsyMetRiC’s risk reports are multifaceted, incorporating numeric probabilities alongside graphical visualizations, ranging from traditional risk charts to innovative ‘heart age’ analogues. This multimodal communication strategy caters to diverse patient preferences and cognitive styles, enhancing comprehension and fostering behavior change. Importantly, educational materials co-produced with individuals with lived experience accompany the application, guiding clinicians on optimal risk discussion techniques to maximize impact.

The research underpinning PsyMetRiC 2.0 is published in the highly regarded journal The Lancet Psychiatry, signaling its scientific rigor and clinical significance. The study employed retrospective multicohort analysis with sophisticated data/statistical methods, ensuring that the model’s validations are both methodologically sound and clinically applicable. Planned future directions include refining the algorithm using results from ongoing qualitative and health economic evaluations, as well as expanding its validation in non-UK populations, including forthcoming trials in the United States.

The developers recognize that health inequities are embedded within many datasets, potentially propagating bias in predictive models. By actively seeking to test and correct for such biases, PsyMetRiC represents an important step toward equitable healthcare delivery. The tool aims to serve patients from diverse ethnic and socioeconomic backgrounds, addressing disparities that have historically marginalized these groups in physical health management.

In summary, PsyMetRiC 2.0 embodies a convergence of advanced analytics, patient-centered design, and regulatory validation, poised to revolutionize the management of cardiometabolic risk in young people with psychosis. Its introduction marks a pivotal moment in psychiatric medicine, promising to reduce premature mortality through early, personalized intervention. As this tool gains traction in clinical settings, it holds the potential to reshape how mental and physical health intersect in vulnerable populations globally.

Subject of Research: People
Article Title: Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0): a retrospective, multicohort clinical prediction model study
News Publication Date: 11-Mar-2026
Web References:

• PsyMetRiC Web Application: https://psymetric.app/
• Lancet Psychiatry Article: https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(25)00398-0/fulltext
  References:
• Perry, B. et al., “Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0),” The Lancet Psychiatry, 2026.
• Original PsyMetRiC Validation Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8211566/
  Keywords: Psychotic disorders, Cardiometabolic risk, Metabolic syndrome, Type 2 diabetes, Obesity, Machine learning, Health equity, Psychiatry, Predictive modeling